提高提供者对有心血管疾病风险患者Lp(a)检测的认识:一项比较研究

IF 4.3 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS American journal of preventive cardiology Pub Date : 2024-11-23 DOI:10.1016/j.ajpc.2024.100895
Wael E. Eid , Emma Hatfield Sapp , Callen Conroy , Coby Bessinger , Cassidy L. Moody , Ryan Yadav , Reece Tolliver , Joseph Nolan , Suzanne M. Francis
{"title":"提高提供者对有心血管疾病风险患者Lp(a)检测的认识:一项比较研究","authors":"Wael E. Eid ,&nbsp;Emma Hatfield Sapp ,&nbsp;Callen Conroy ,&nbsp;Coby Bessinger ,&nbsp;Cassidy L. Moody ,&nbsp;Ryan Yadav ,&nbsp;Reece Tolliver ,&nbsp;Joseph Nolan ,&nbsp;Suzanne M. Francis","doi":"10.1016/j.ajpc.2024.100895","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Lipoprotein(a) [Lp(a)] is a low-density lipoprotein variant with atherogenic, thrombogenic, and pro-inflammatory properties that may have numerous pathologic effects, including dyslipidemia. Screening for Lp(a) is clinically significant, due to its causal role in atherosclerotic cardiovascular disease (ASCVD). Among clinicians, however, there remains a general lack of both clinical awareness of Lp(a) and adequate tools to track Lp(a) testing in patients.</div></div><div><h3>Objective</h3><div>To study factors affecting Lp(a) screening by: i) determining the effectiveness of messaging providers at a large community health system about Lp(a) screening and measuring the subsequent percentage of Lp(a) tests requested; and ii) by determining the percentage of patients who obtained Lp(a) testing after being advised by the provider.</div></div><div><h3>Methods</h3><div>From December 2022 through March 2023, messages detailing the need for Lp(a) screening were sent via the Epic EHR™ to providers of patients meeting criteria for Lp(a) testing in advance of scheduled patient appointments. In this prospective study, providers were randomized into 2 groups: those receiving the pre-appointment message (Group 1) and those not receiving the pre-appointment message (Group 2).</div></div><div><h3>Results</h3><div>Sending pre-appointment messages correlated with more Lp(a) orders (16.6 % v. 4.7 %, <em>P</em> &lt; 0.001) and consequently with more tests performed (10.2 % v. 3.7 %, <em>p</em> &lt; 0.001). Among provider types, nurse practitioners and physician assistants had the highest number of Lp(a) results per order (<em>Z</em> = 16.40, <em>P</em> &lt; 0.001), achieving 30.8–39.1 % more test results, even if they did not receive the pre-appointment message. Distribution of Lp(a) values in patients was 59.7 % ≤ 29 mg/dL; 9.7 % &gt; 29 and &lt; 50mg/dL; and 30.6 % ≥ 50 mg/dL.</div></div><div><h3>Conclusion</h3><div>Providers who received pre-appointment messages via an EHR were associated with requesting more tests and consequently receiving more Lp(a) results, compared with providers who did not receive messages.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100895"},"PeriodicalIF":4.3000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666892/pdf/","citationCount":"0","resultStr":"{\"title\":\"Increasing provider awareness of Lp(a) testing for patients at risk for cardiovascular disease: A comparative study\",\"authors\":\"Wael E. Eid ,&nbsp;Emma Hatfield Sapp ,&nbsp;Callen Conroy ,&nbsp;Coby Bessinger ,&nbsp;Cassidy L. Moody ,&nbsp;Ryan Yadav ,&nbsp;Reece Tolliver ,&nbsp;Joseph Nolan ,&nbsp;Suzanne M. Francis\",\"doi\":\"10.1016/j.ajpc.2024.100895\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Lipoprotein(a) [Lp(a)] is a low-density lipoprotein variant with atherogenic, thrombogenic, and pro-inflammatory properties that may have numerous pathologic effects, including dyslipidemia. Screening for Lp(a) is clinically significant, due to its causal role in atherosclerotic cardiovascular disease (ASCVD). Among clinicians, however, there remains a general lack of both clinical awareness of Lp(a) and adequate tools to track Lp(a) testing in patients.</div></div><div><h3>Objective</h3><div>To study factors affecting Lp(a) screening by: i) determining the effectiveness of messaging providers at a large community health system about Lp(a) screening and measuring the subsequent percentage of Lp(a) tests requested; and ii) by determining the percentage of patients who obtained Lp(a) testing after being advised by the provider.</div></div><div><h3>Methods</h3><div>From December 2022 through March 2023, messages detailing the need for Lp(a) screening were sent via the Epic EHR™ to providers of patients meeting criteria for Lp(a) testing in advance of scheduled patient appointments. In this prospective study, providers were randomized into 2 groups: those receiving the pre-appointment message (Group 1) and those not receiving the pre-appointment message (Group 2).</div></div><div><h3>Results</h3><div>Sending pre-appointment messages correlated with more Lp(a) orders (16.6 % v. 4.7 %, <em>P</em> &lt; 0.001) and consequently with more tests performed (10.2 % v. 3.7 %, <em>p</em> &lt; 0.001). Among provider types, nurse practitioners and physician assistants had the highest number of Lp(a) results per order (<em>Z</em> = 16.40, <em>P</em> &lt; 0.001), achieving 30.8–39.1 % more test results, even if they did not receive the pre-appointment message. Distribution of Lp(a) values in patients was 59.7 % ≤ 29 mg/dL; 9.7 % &gt; 29 and &lt; 50mg/dL; and 30.6 % ≥ 50 mg/dL.</div></div><div><h3>Conclusion</h3><div>Providers who received pre-appointment messages via an EHR were associated with requesting more tests and consequently receiving more Lp(a) results, compared with providers who did not receive messages.</div></div>\",\"PeriodicalId\":72173,\"journal\":{\"name\":\"American journal of preventive cardiology\",\"volume\":\"21 \",\"pages\":\"Article 100895\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-11-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666892/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of preventive cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666667724002630\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of preventive cardiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666667724002630","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:脂蛋白(a) [Lp(a)]是一种低密度脂蛋白变体,具有致动脉粥样硬化、血栓形成和促炎特性,可能具有许多病理效应,包括血脂异常。由于Lp(a)在动脉粥样硬化性心血管疾病(ASCVD)中起因果作用,因此筛查Lp(a)具有重要的临床意义。然而,在临床医生中,仍然普遍缺乏Lp(a)的临床意识和足够的工具来跟踪患者的Lp(a)检测。目的:通过以下方式研究影响Lp(a)筛查的因素:i)确定大型社区卫生系统中Lp(a)筛查的信息提供者的有效性,并测量随后要求进行Lp(a)测试的百分比;ii)确定在提供者建议下接受Lp(a)检测的患者百分比。方法:从2022年12月到2023年3月,详细说明Lp(a)筛查需求的信息通过Epic EHR™发送给符合Lp(a)检测标准的患者的提供者,提前安排患者预约。在这项前瞻性研究中,提供者被随机分为两组:接受预约前信息的(第1组)和未接受预约前信息的(第2组)。结果:发送预约前信息与更多的Lp(a)订单相关(16.6% vs . 4.7%, P < 0.001),因此进行了更多的测试(10.2% vs . 3.7%, P < 0.001)。在提供者类型中,执业护士和医师助理每个订单的Lp(a)结果数量最高(Z = 16.40, P < 0.001),即使他们没有收到预约前信息,也能获得30.8- 39.1%的测试结果。Lp(a)值在患者中的分布为59.7%≤29 mg/dL;9.7% bbb29和< 50mg/dL;≥50mg /dL的占30.6%。结论:与没有收到信息的提供者相比,通过电子病历收到预约前信息的提供者要求更多的检查,从而收到更多的Lp(a)结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Increasing provider awareness of Lp(a) testing for patients at risk for cardiovascular disease: A comparative study

Background

Lipoprotein(a) [Lp(a)] is a low-density lipoprotein variant with atherogenic, thrombogenic, and pro-inflammatory properties that may have numerous pathologic effects, including dyslipidemia. Screening for Lp(a) is clinically significant, due to its causal role in atherosclerotic cardiovascular disease (ASCVD). Among clinicians, however, there remains a general lack of both clinical awareness of Lp(a) and adequate tools to track Lp(a) testing in patients.

Objective

To study factors affecting Lp(a) screening by: i) determining the effectiveness of messaging providers at a large community health system about Lp(a) screening and measuring the subsequent percentage of Lp(a) tests requested; and ii) by determining the percentage of patients who obtained Lp(a) testing after being advised by the provider.

Methods

From December 2022 through March 2023, messages detailing the need for Lp(a) screening were sent via the Epic EHR™ to providers of patients meeting criteria for Lp(a) testing in advance of scheduled patient appointments. In this prospective study, providers were randomized into 2 groups: those receiving the pre-appointment message (Group 1) and those not receiving the pre-appointment message (Group 2).

Results

Sending pre-appointment messages correlated with more Lp(a) orders (16.6 % v. 4.7 %, P < 0.001) and consequently with more tests performed (10.2 % v. 3.7 %, p < 0.001). Among provider types, nurse practitioners and physician assistants had the highest number of Lp(a) results per order (Z = 16.40, P < 0.001), achieving 30.8–39.1 % more test results, even if they did not receive the pre-appointment message. Distribution of Lp(a) values in patients was 59.7 % ≤ 29 mg/dL; 9.7 % > 29 and < 50mg/dL; and 30.6 % ≥ 50 mg/dL.

Conclusion

Providers who received pre-appointment messages via an EHR were associated with requesting more tests and consequently receiving more Lp(a) results, compared with providers who did not receive messages.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
American journal of preventive cardiology
American journal of preventive cardiology Cardiology and Cardiovascular Medicine
CiteScore
6.60
自引率
0.00%
发文量
0
审稿时长
76 days
期刊最新文献
Under-recognized cardiovascular risk enhancers in women: A call to rethink clinical assessment on risk stratification Unhealthy alcohol use and risk of coronary heart disease among young and middle-aged adults Impact of payer rejections and out-of-pocket costs on patient access to bempedoic acid therapy Inflammatory markers and calcification of coronary arteries, aorta and cardiac valves: Findings from the atherosclerosis risk in communities study Composite cardiovascular risk factor control in US adults with diabetes and relation to social determinants of health: The All of Us research program
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1